Guardant Health, Inc. acquisition history.

Guardant purchased all of the remaining shares of Guardant Health AMEA, Inc. held by SoftBank (SVF Excalibur (Cayman) Limited) and its affiliates, giving Guardant full control over its liquid-biopsy operations across the Asia, Middle East and Africa region. The AMEA entity, established in May 2018 as a joint venture between Guardant Health and the SoftBank Vision Fund, serves 41 countries across the region. The purchase price of $177.8 million was determined based on an independent third-party valuation, and the joint venture agreement was terminated concurrently with the closing.

In December 2025 Guardant Health purchased all of the outstanding shares of MetaSight Diagnostics Ltd., a health technology company. The transaction included $59.0 million in upfront cash consideration paid at closing, plus up to $90.0 million in variable contingent consideration tied to future commercial performance and regulatory approvals of the MetaSight technology. Total purchase consideration net of cash acquired was $93.0 million, with the contingent consideration carried at a fair value of $34.0 million as of the acquisition date. The excess of purchase consideration over the fair value of net assets acquired was recorded as goodwill, attributable to future revenue opportunities Guardant expects from leveraging the acquired technologies.